Common Side Effects Reported Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists: Nausea most frequent, especially during dose escalation Vomiting typically mild to moderate, subsiding with continued use Diarrhea and constipation fluctuating depending on individual tolerance Abdominal discomfort transient and often improved over time Dose-Response Relationship At lower doses (14 mg weekly), side effects were generally mild and manageable, though some participants still reported early GI symptoms
Regulated and safe , with side effects that are monitored and managed
The combination of weight loss and improved blood sugar control achieved with retatrutide offers a comprehensive approach to managing type 2 diabetes and its associated comorbidities
[20] [21] When patients achieve substantial weight loss through GLP-1 therapy, the biomechanical burden on these joints decreases proportionally
The reconstitution chart assumes your peptide is intact
Retatrutides side effects are primarily GI-related and manageable for most users
